Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD

被引：19

作者：

Donohue, James F. ^{[1
]}

Rheault, Tara ^{[2
,4
]}

MacDonald-Berko, Margot ^{[2
]}

Bengtsson, Thomas ^{[3
]}

Rickard, Kathleen ^{[2
]}

机构：

[1] Univ N Carolina, Sch Med, Div Pulm & Crit Care Med, Chapel Hill, NC USA

[2] Verona Pharm Plc, Raleigh, NC USA

[3] Stat Mind AB, Lund, Sweden

[4] Verona Pharm, 8045 Arco Corp Dr,Suite 130, Raleigh, NC 27617 USA

来源：

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2023年 / 18卷

关键词：

RPL554; nebulized therapy; chronic obstructive pulmonary disease; clinical efficacy; drug development; 4 INHIBITOR ENSIFENTRINE; DUAL PHOSPHODIESTERASE-3; PDE4; INHIBITOR; RPL554; PHARMACOLOGY; EFFICACY; ASTHMA; PDE3/4; SAFETY;

D O I：

10.2147/COPD.S413436

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.

引用

页码：1611 / 1622

页数：12

共 41 条

[1] Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases [J].

Abbott-Banner, Katharine H. ;

Page, Clive P. .

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 114 (05) :365-376

[2]

[Anonymous], 2023, Global Strategy for the Diagnosis, Managment, and Prevention of Chronic Obstructive Pulmonary Disease

[3]

[Anonymous], 2020, DALIRESP ROFL PRESCR

[4] Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials) [J].

Anzueto, Antonio ;

Barjaktarevic, Igor Z. ;

Siler, Thomas M. ;

Rheault, Tara ;

Bengtsson, Thomas ;

Rickard, Kathleen ;

Sciurba, Frank .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) :406-416

[5] Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease [J].

Banner, Katharine H. ;

Press, Neil J. .

BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (06) :892-906

[6] Nebulized Therapies in COPD: Past, Present, and the Future [J].

Barjaktarevic, Igor Z. ;

Milstone, Aaron P. .

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 :1665-1677

[7] The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one] [J].

Boswell-Smith, Victoria ;

Spina, Domenico ;

Oxford, Alec W. ;

Comer, Mike B. ;

Seeds, Esther A. ;

Page, Clive P. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (02) :840-848

[8] Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [J].

Calverley, Peter M. A. ;

Rabe, Klaus F. ;

Goehring, Udo-Michael ;

Kristiansen, Soren ;

Fabbri, Leonardo M. ;

Martinez, Fernando J. .

LANCET, 2009, 374 (9691) :685-694

[9] Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways [J].

Calzetta, Luigino ;

Cazzola, Mario ;

Page, Clive P. ;

Rogliani, Paola ;

Facciolo, Francesco ;

Matera, Maria Gabriella .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 32 :15-23

[10] Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone [J].